Abstract
Clopidogrel, an antiplatelet agent, prevents platelet aggregation by inhibiting the adenosine disphosphate (ADP) P2Y12 receptor, which is located on the platelet surface. Although dual antiplatelet therapy appears to be efficient, a considerable number of patients continue to experience adverse cardiovascular events, such as stent thrombosis. The percentage of low response to antiplatelet therapy varies from 4% to 30% of patients depending on the cut-off values. In addition, several factors such as poor absorption, drug-to-drug interactions, inadequate dosing, elevated body mass index, insulin resistance and the nature of acute coronary syndromes have been implicated in low clopidogrel response. Recently, studies have focused on the role of genetic polymorphisms encoding enzymes that participate in clopidogrel hepatic metabolism or receptors involved in intestinal absorption and ADP induced platelet aggregation, which may affect the percentage of platelet inhibition after clopidogrel administration. The management of clopidogrel resistance remains a controversial issue and additional studies are required to evaluate the safety and efficacy of increased loading of clopidogrel or replacement with other new antiplatelet agents such as prasugrel.
Keywords: Clopidogrel resistance, cytochrome P450, gene polymorphisms, platelets, thrombus, Clopidogrel, atherosclerosis, adenosine disphosphate, atherosclerotic disease, multifactorial pattern, cytochrome, carbon monoxide, enzymes, phospholipids, detoxification, coagulation, body mass index, polymorphisms, platelet, healthy Caucasians, coronary artery disease, erythromycin, antiplatelet therapy, percentile distribution, platelet function analyzer (PFA), vasodilator, phosphoprotein
Current Medicinal Chemistry
Title: The Role of the Cytochrome P450 Polymorphisms in Clopidogrel Efficacy and Clinical Utility
Volume: 18 Issue: 3
Author(s): D. Tousoulis, G. Siasos, M. Zaromytidou, N. Papageorgiou, E. Stefanadi, E. Oikonomou and C. Stefanadis
Affiliation:
Keywords: Clopidogrel resistance, cytochrome P450, gene polymorphisms, platelets, thrombus, Clopidogrel, atherosclerosis, adenosine disphosphate, atherosclerotic disease, multifactorial pattern, cytochrome, carbon monoxide, enzymes, phospholipids, detoxification, coagulation, body mass index, polymorphisms, platelet, healthy Caucasians, coronary artery disease, erythromycin, antiplatelet therapy, percentile distribution, platelet function analyzer (PFA), vasodilator, phosphoprotein
Abstract: Clopidogrel, an antiplatelet agent, prevents platelet aggregation by inhibiting the adenosine disphosphate (ADP) P2Y12 receptor, which is located on the platelet surface. Although dual antiplatelet therapy appears to be efficient, a considerable number of patients continue to experience adverse cardiovascular events, such as stent thrombosis. The percentage of low response to antiplatelet therapy varies from 4% to 30% of patients depending on the cut-off values. In addition, several factors such as poor absorption, drug-to-drug interactions, inadequate dosing, elevated body mass index, insulin resistance and the nature of acute coronary syndromes have been implicated in low clopidogrel response. Recently, studies have focused on the role of genetic polymorphisms encoding enzymes that participate in clopidogrel hepatic metabolism or receptors involved in intestinal absorption and ADP induced platelet aggregation, which may affect the percentage of platelet inhibition after clopidogrel administration. The management of clopidogrel resistance remains a controversial issue and additional studies are required to evaluate the safety and efficacy of increased loading of clopidogrel or replacement with other new antiplatelet agents such as prasugrel.
Export Options
About this article
Cite this article as:
Tousoulis D., Siasos G., Zaromytidou M., Papageorgiou N., Stefanadi E., Oikonomou E. and Stefanadis C., The Role of the Cytochrome P450 Polymorphisms in Clopidogrel Efficacy and Clinical Utility, Current Medicinal Chemistry 2011; 18 (3) . https://dx.doi.org/10.2174/092986711794839151
DOI https://dx.doi.org/10.2174/092986711794839151 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Critical Illness in Obstetric Patients: Venous Thromboembolism in Pregnancy
Current Women`s Health Reviews Tea and Health: Studies in Humans
Current Pharmaceutical Design Therapeutic Effects of Melatonin On Liver And Kidney Damages In Intensive Exercise Model of Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Hypolipidaemic Drug Treatment: Yesterday is Not Gone Yet, Today is Challenging and Tomorrow is Coming Soon; let us Combine them all
Current Pharmaceutical Design Combining Diffusion-Weighted Imaging Patterns with ABCD2 Score Predicts Stroke Risk after Transient Ischemic Attack
Current Neurovascular Research CD31+ Circulating Angiogenic Cell Number and Subtypes are Reduced in Individuals with Chronic Stroke
Current Neurovascular Research Phosphodiesterase 5 Inhibitors - Drug Design and Differentiation Based on Selectivity, Pharmacokinetic and Efficacy Profiles
Current Pharmaceutical Design Depression and Self-Efficacy in Patients with Type 2 Diabetes in Northern Greece
Endocrine, Metabolic & Immune Disorders - Drug Targets Severe Influenza: Clinical Features and Treatment Options
Current Respiratory Medicine Reviews The Quality of Life of Thalassemic Patients: The Role of Endocrine Defect Compensation
Endocrine, Metabolic & Immune Disorders - Drug Targets New-onset Diabetes Mellitus: Predictive Factors and Impact on the Outcome of Patients Undergoing Liver Transplantation
Current Diabetes Reviews Identifying Novel Targets for Treatment of Liver Fibrosis: What Can We Learn from Injured Tissues which Heal Without a Scar?
Current Drug Targets Response to <i>Letter to the Editor</i> by Briana and Malamitsi-Puchner: Effects of Pregnancy-induced Insulin Resistance on the Fetus and the Future Development of Metabolic Diseases in Adulthood
Current Vascular Pharmacology Pancreatic Cancer in Obesity: Epidemiology, Clinical Observations, and Basic Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Continuous Positive Airway Pressure Treatment in Patients with Sleep Apnoea: Does it Really Improve Glucose Metabolism?
Current Diabetes Reviews Is Red Meat Required for the Prevention of Iron Deficiency Among Children and Adolescents?
Current Pediatric Reviews Prognostic Value of Copeptin in Chronic Kidney Disease: From General Population to End-Stage Renal Disease
Current Protein & Peptide Science Lipid-Based Systems for Delivery of Biological Macromolecules
Recent Patents on Nanomedicine Cardiovascular Effects of Antiretroviral Drugs: Clinical Review
Cardiovascular & Hematological Disorders-Drug Targets High Sensitivity C-Reactive Protein (hsCRP): A New Biochemical Marker of Atherosclerotic Vascular Disease
Current Cardiology Reviews